Guardia-Baena Juan Manuel, Carcelén-Fraile María Del Carmen, Hita-Contreras Fidel, Aibar-Almazán Agustín, Arévalo-Ruíz María de Los Ángeles, Mesas-Aróstegui María Aurora, Fábrega-Cuadros Raquel
Department of Endocrinology and Nutrition, Virgen de las Nieves University Hospital, 18014 Granada, Spain.
Department of Educational Sciences, Faculty of Social Sciences, University of Atlántico Medio, 35017 Las Palmas de Gran Canaria, Spain.
Nutrients. 2025 Mar 29;17(7):1206. doi: 10.3390/nu17071206.
BACKGROUND/OBJECTIVES: Sarcopenia and sarcopenic obesity (SO) are related to an increased risk of adverse outcomes. The objective of this study was to assess the internal and clinical validation of the Spanish version of the SARC-Global questionnaire, a sarcopenia risk screening tool, and its ability to detect sarcopenia, severe sarcopenia, and SO in adults aged ≥ 60 years.
A total of 167 participants (73.22 ± 6.70 years, 71.26% women) completed the study. First, reliability was assessed by the inter-rater and the test-retest analyses. For the clinical validation, the risk of sarcopenia (SARC-Global) was compared to sarcopenia diagnosed using three operational definitions. The SARC-Global's ability to detect severe sarcopenia (SS) and sarcopenic obesity assessed with body mass index (SO-BMI) and body fat percentage (SO-BFP), considering nutritional status and physical activity level, was also analyzed.
The Spanish SARC-Global questionnaire showed a substantial to excellent inter-rater and test-retest reliability. Regarding the clinical validation, sensitivity/specificity values to detect cases of sarcopenia were 85.71%/64.38% (EWGSOP2), 83.33%/65.81% (FNIH), and 54.55%/63.46% (AWGS-2019). Diagnostic accuracy ranged from 67.07% (FNIH) to 62.87% (AWGS-2019). The analysis also indicated that SARC-Global cutoff of 13.5 was the optimal score for severe sarcopenia (100.00% sensitivity and 80.49% specificity), SO-BMI (100% sensitivity and 80.49% specificity), and SO-PBF (80.00% sensitivity and 80.86% specificity).
The Spanish version of the SARC-Global questionnaire is a reliable and clinically valid instrument for identifying people at the risk of sarcopenia, severe sarcopenia, and sarcopenic obesity in Spanish older adults.
背景/目的：肌肉减少症和肌肉减少性肥胖（SO）与不良后果风险增加相关。本研究的目的是评估肌肉减少症风险筛查工具SARC-全球问卷西班牙语版的内部验证和临床验证，以及其在60岁及以上成年人中检测肌肉减少症、严重肌肉减少症和SO的能力。
共有167名参与者（73.22±6.70岁，71.26%为女性）完成了研究。首先，通过评分者间和重测分析评估信度。对于临床验证，将肌肉减少症风险（SARC-全球问卷）与使用三种操作定义诊断的肌肉减少症进行比较。还分析了SARC-全球问卷在考虑营养状况和身体活动水平的情况下，检测严重肌肉减少症（SS）和用体重指数（SO-BMI）及体脂百分比（SO-BFP）评估的肌肉减少性肥胖的能力。
西班牙语版SARC-全球问卷显示出评分者间和重测信度从高到优。关于临床验证，检测肌肉减少症病例的敏感性/特异性值分别为85.71%/64.38%（EWGSOP2）、83.33%/65.81%（FNIH）和54.55%/63.46%（AWGS-2019）。诊断准确性范围为67.07%（FNIH）至62.87%（AWGS-2019）。分析还表明，SARC-全球问卷13.5的临界值是严重肌肉减少症（敏感性100.00%，特异性80.49%）、SO-BMI（敏感性100%，特异性80.49%）和SO-PBF（敏感性80.00%，特异性80.86%）的最佳分数。
西班牙语版SARC-全球问卷是一种可靠且临床有效的工具，可用于识别西班牙老年人群中存在肌肉减少症、严重肌肉减少症和肌肉减少性肥胖风险的人群。
Zotero 插件